32 results about "5 Alpha-Reductase Inhibitor" patented technology

This invention provides for combinations of 5 alpha reductase inhibitors and SERMs. These combinations are useful in: 1) preventing prostate carcinogenesis in a subject;2) preventing the recurrence of, suppressing, inhibiting or reducing the incidence of prostate carcinogenesis in a subject; 3) treating a subject with prostate cancer; 4) suppressing, inhibiting or reducing the incidence of prostate cancer in a subject; 5) treating a subject with pre-malignant lesions of prostate cancer; 6) suppressing, inhibiting or reducing the incidence of pre-malignant lesions of prostate cancer in a subject; 7) reducing the incidence, inhibiting, suppressing, preventing and / or treating androgen-deprivation induced conditions in men suffering from prostate cancer, such as androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), hot flashes and / or gynecomastia.; and 8) treating polycystic ovarian syndrome and reducing the incidence, inhibiting, suppressing, preventing and / or treating diabetes, cardiovascular disease, breast cancer and endometrial cancer in women suffering from polycystic ovarian syndrome.

Disclosed are methods to induce dislodgement of target prostatic cells from the prostate organ, collecting said cells, and subsequently examining the cell population. Such methods comprise the administration of an agent that facilitates the dislodgement of the target cells from within the prostate, which then migrate into the urethra. Exemplary agents include 5 alpha-reductase inhibitors. The cells induced to pass into the urethra are then collected non-invasively, such as through urine or semen samples. Such collection is further strategically calculated relative the administration of the agent so as to maximize the sample collection of the target cells of interest. The exfoliated prostatic epithelial cells are subsequently utilized for purposes such as detecting prostate cancer, predicting / measuring prostate tumor susceptibility to drug regimes, active surveillance of patients whose prostate biopsy results are negative, but continue to exhibit symptoms consistent with prostate cancer, and identifying false positive results associated with biomarker assays.

The invention discloses novel endocrine treatment phytochemicals which affect androgenic status. The method for treatment of 5-alpha-reductase responsive diseases using four novel 5-alpha-reductase inhibitor compounds; leucoanthocyanidin, glabrene, glabridin, and alpha-terpineol is disclosed. Glabridin does not interfere with normal testosterone to androgen receptor binding.

An application of galanga galangal fruit and its extract in preparing 5 alpha-reductase inhibitor and the medicines for treating prostatoplasia with high curative effect is disclosed.

The invention discloses a xanthone compound (1) capable of inhibiting 5 alpha-reductase. The xanthone compound is extracted from Swertia atroviolacea, the molecular formula is C18H18O5, the compound is named as: 6-(2-hydroxyethyl) -1,7-dimethoxy-3-methyl-xanthone, the xanthone compound has the structural formula which is defined in the description. The preparation method of the xanthone compound comprises the following steps: using the Swertia atroviolacea as the raw material, subjecting the raw material to extracting, MCI decoloration, silica gel column chromatography and high-pressure liquid chromatography to obtain the xanthone compound. The 5 alpha-reductase activity test on the xanthone compound shows that the xanthone compound has relatively good inhibition effect on the 5 alpha-reductase and the compound can be used as a lead compound for preparing a 5 alpha-reductase inhibitor.

The invention discloses phenylpropanoid compounds as well as a preparation method and an application thereof. The phenylpropanoid compounds are separated from Swertia atroviolacea, are named 3-hydroxy-1-(6-hydroxymethyl-1,3-dihydroisobenzofuran-5-yl)propan-1-one and have the structural formula shown in the specification, and a molecular formula of the phenylpropanoid compounds is C12H14O4. The preparation method of the phenylpropanoid compounds comprises the following steps: the Swertia atroviolacea is taken as the raw material and subjected to extract extraction, MCI decoloration, silica gel column chromatography and HPLC (high performance liquid chromatography) separation. 5 alpha-reductase activity tests prove that the phenylpropanoid compounds have better inhibition function on 5 alpha-reductase. The invention further discloses the preparation method and the application of the phenylpropanoid compounds. The compounds are simple in structure, have better 5 alpha-reductase inhibition function and can serve as lead compounds for preparing 5 alpha-reductase inhibitors.